Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Psoriasis treatment concept | Sviatlana - stock.adobe.com
Beyond the Surface: How New Therapies, Patient-Centered Care Are Changing Psoriasis Outcomes

August 19th 2025

National Psoriasis Awareness Month offers an opportunity to examine how advances in systemic therapy, combined with patient-centered care models, are reshaping the treatment landscape.

traffic-related air pollution | Sergiy Serdyuk - stock.adobe.com
Air Pollution, Genes Together Raise Psoriasis Risk, Study Finds

August 14th 2025

Psoriasis in older woman | Image credit: ajr_images - stock.adobe.com
Tildrakizumab Found Effective, Safe in Elderly Patients With Psoriasis

August 12th 2025

Biosimilars. | Image Credit: Shutter2U - stock.adobe.com
Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

August 11th 2025

Family planning/consult | Image credit: Satori Studio - stock.adobe.com
Patients With Psoriasis Seek Better Family Planning Guidance

August 5th 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
August 21st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 21st 2025

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professionals

August 19, 2025 | 1:00 PM & 8:00 PM ET
August 21st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Payer Considerations When Treating Psoriasis With Different Therapeutics
December 21st 2021

Payer Considerations When Treating Psoriasis With Different Therapeutics

Drs Groves and Lebwohl discuss payer considerations for ensuring treatment with the appropriate agent for patients with psoriasis and metabolic syndrome.
Psoriasis top 5 articles
December 20th 2021

Top 5 Most-Read Psoriasis Articles of 2021

Matthew Gavidia
The top 5 most-read psoriasis articles of 2021 on AJMC.com covered risk factors involved in the pathogenesis and treatment of psoriatic disease and cost considerations for treatment.
Spotlighting a patient.
December 18th 2021

Study Finds No Standardized Treatment, Continued Health Care Utilization in Pustular Psoriasis

Matthew Gavidia
A case series of patients with pustular psoriasis indicated a lack of standardized treatment and continued health care utilization, in which men were at greater risk of an emergency department or hospital encounter.
Doctor and patient.
December 15th 2021

Comorbid Psoriasis, NAFLD Linked With Significantly Impaired Kidney Function

Matthew Gavidia
Patients with comorbid nonalcoholic fatty liver disease (NAFLD) and chronic plaque psoriasis were shown to have significantly lower estimated glomerular filtration rate levels and greater prevalence of more advanced chronic kidney disease.
Effectiveness of Treatment Options in Patients With Psoriasis and MetS
December 15th 2021

Effectiveness of Treatment Options in Patients With Psoriasis and MetS

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, elaborate on treatment effectiveness in patients with both psoriasis and metabolic syndrome.
Increased Risk of Metabolic Syndrome in Patients With Psoriasis
December 15th 2021

Increased Risk of Metabolic Syndrome in Patients With Psoriasis

Drs Lebwohl and Groves discuss patients with psoriasis and the increased risk they have for also being diagnosed with metabolic syndrome.
Patient Adherence With Psoriasis Treatments
December 13th 2021

Patient Adherence With Psoriasis Treatments

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, explain the difficulties of patient adherence to psoriasis treatments.
Disease Burden for Patients With Plaque Psoriasis
December 13th 2021

Disease Burden for Patients With Plaque Psoriasis

Dr Mark Lebwohl explains disease burden for patients with plaque psoriasis and discusses the common comorbidities clinicians see.
Physician with patient.
December 9th 2021

Nail Involvement May Reduce Efficacy of Ustekinumab For Psoriasis

Matthew Gavidia
Nail involvement was shown to reduce the effectiveness of ustekinumab in the treatment of moderate to severe psoriasis, whereas secukinumab exhibited overall higher efficacy than ustekinumab and similar response rates regardless of nail involvement.
Person clasping hand.
December 6th 2021

Patients With Psoriatic Disease May Have Greater Risk of VTE, PVD

Matthew Gavidia
Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.
Person touching neck.
December 2nd 2021

Brodalumab Improves Skin Clearance, QOL vs Ustekinumab in Comorbid Psoriasis, PsA

Matthew Gavidia
Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).
Physician and patient.
November 29th 2021

TNF Inhibitors Show Real-world Efficacy on QOL of Patients With Nail Psoriasis, PsA

Matthew Gavidia
Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.
Magnifying risk in one person of a group.
November 26th 2021

Assessing Risk Factors for PsA Development in Patients With Psoriasis

Matthew Gavidia
Use of biologics and age may influence risk of psoriatic arthritis (PsA) development in patients with psoriasis, according to findings presented at the 2021 American College of Rheumatology Annual Meeting.
Health care cost.
November 20th 2021

Greater Work Impairment, Comorbidity Burden Linked With Concomitant Psoriasis, PsA

Matthew Gavidia
Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.
Elderly person's hands.
November 17th 2021

Guselkumab Linked With Long-term Improvement of Joint Manifestations, Disease Activity in PsA

Matthew Gavidia
Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.
Pill bottle.
November 12th 2021

Prior Biologic Use, Body Weight May Impact Guselkumab Efficacy in Psoriasis

Matthew Gavidia
Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.
Psoriasis on hand.
November 9th 2021

Real-world Findings Show Apremilast Effective Long Term in Plaque Psoriasis

Matthew Gavidia
Findings of a real-world, single-center study indicated that apremilast was effective and safe long-term in the treatment of moderate-to-severe plaque psoriasis.
Arthritis pain in hands.
November 3rd 2021

Ixekizumab Linked With Improved Outcomes vs Adalimumab in PsA With Concomitant Psoriasis

Matthew Gavidia
A greater proportion of biologic-naive patients with psoriatic arthritis treated with ixekizumab vs adalimumab achieved the combined endpoint of 100% resolution in the Psoriasis Area Severity Index and 50% or greater improvement in the American College of Rheumatology criteria at week 24 and 52.
Site Logo
November 1st 2021

Economic Burden of Joint Disease in Psoriasis: US Claims Analysis

Patricia Prince, MPH Michelle Skornicki, MPH Robert Suruki, ScD Edward Lee, PharmD Anthony Louder, PhD
This retrospective claims analysis found that concomitant joint disease in psoriasis is associated with greater health care resource utilization and health care costs than psoriasis alone.
Arrow of people.
October 29th 2021

Biologic Treatment, Smoking May Increase Psoriasis Risk in Patients With IBD

Matthew Gavidia
Patients with inflammatory bowel disease (IBD) treated with adalimumab had greater risk of developing psoriasis than those administered infliximab, with gender and smoking incidence also linked with greater IBD risk.
Physician evaluating pill bottle.
October 26th 2021

Biologic, Antirheumatic Drug Use May Increase Risk of Adverse Pregnancy Outcomes in Women With Psoriasis

Matthew Gavidia
Pregnant women with psoriasis were found to be at increased risk of experiencing preterm birth and Cesarean delivery, with patients undergoing anti-rheumatic treatment during their first pregnancy indicated to be at significantly greater risk.
AMCP Studies Highlight Workplace Costs of Skin Care
October 21st 2021

AMCP Studies Highlight Workplace Costs of Skin Care

Tony Hagen
Studies presented at Academy of Managed Care Pharmacy Nexus 2021 elucidated costs of skin treatment for workers in terms of recovery time taken and percentage of salary.
Health charts.
October 20th 2021

Ixekizumab Improves Retention vs Secukinumab in Patients With Psoriasis

Matthew Gavidia
Biologic-experienced patients with psoriasis exhibited significantly improved treatment adherence and lower discontinuation, nonpersistence, and switching rates over 18 months when prescribed ixekizumab vs secukinumab.
Frustrated young adult.
October 15th 2021

Evaluating Treatment Goals, Preferences in Parents and Young Patients With Psoriasis

Matthew Gavidia
Pediatric populations, young adults, and parents all identified differing goals and preferences of treatment for psoriasis, with the most important treatment goals overall cited as lesion prevention and reduction.
Person scratching neck.
October 13th 2021

Novel Calcipotriene, Betamethasone Dipropionate Cream Linked With Improved Outcomes and QOL in Psoriasis

Matthew Gavidia
A novel formulation of calcipotriene (CAL), betamethasone dipropionate (BDP) cream was found to be more effective, provide superior quality of life, and safe in patients with psoriasis, compared with standard CAL/BDP topical suspension/gel.
Physician speaking with patient.
October 9th 2021

Evaluating Common Conditions That Precede Psoriatic Arthritis Diagnosis

Matthew Gavidia
Patients with psoriatic arthritis (PsA) were found to be more likely to report musculoskeletal symptoms and dermatologic issues prior to initial PsA diagnosis.
Physician checking patient's hand.
October 6th 2021

Brodalumab May Enhance Skin Clearance, QOL vs Ustekinumab for Psoriasis

Matthew Gavidia
Patients with moderate to severe psoriasis were shown to achieve and maintain higher levels of complete skin clearance and quality of life when treated with brodalumab vs ustekinumab, regardless of the presence of lifestyle risk factors.
Patient and physician.
October 1st 2021

High Rate of Secukinumab Retention Shown Long Term in Patients With Psoriasis

Matthew Gavidia
Secukinumab was associated with a high rate of short- and long-term drug survival in the treatment of patients with psoriasis, with factors such as obesity and prior biologic use linked to discontinuation of use.
Physician and patient.
September 29th 2021

Positive Fecal Immunochemistry Test May Increase Risk of Psoriasis

Matthew Gavidia
Patients with a positive fecal immunochemistry test (FIT) were shown to be at significantly greater risk of developing psoriasis than those with FIT-negative tests.
Person smoking a cigarette.
September 25th 2021

Smoking, Periodontitis Linked With Increased Risk of Psoriasis

Matthew Gavidia
Patients with periodontitis had a potential increased risk of developing psoriasis, particularly those who smoked.
<1
...
5678910111213
...
16>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo